Myocarditis and pericarditis in adolescents after first and second doses of mRNA COVID-19 vaccines
Myocarditis and pericarditis in adolescents after first and second doses of mRNA COVID-19 vaccines
复制标题
DOI：
10.1093/ehjqcco/qcab090
复制
发表时间：
2022-01-17
影响因子：
5.2
通讯作者：
Montastruc, Francois
中科院分区：
文献类型：
--
作者：
Foltran, Deborah;Delmas, Clement;Montastruc, Francois
目的虽然疫苗接种相关的心包炎和/或心肌炎引起了一些关注，但在青少年年龄组，特别是12-15岁的人群中，还没有关于接种新冠肺炎基因疫苗的心包炎和/或心肌炎的已发表数据。本研究的目的是确定在12至17岁的青少年中，使用新冠肺炎基因疫苗报告心包炎和/或心肌炎的风险是否因接种剂量、年龄、性别和心包炎和/或心肌炎的类型而异。方法和结果我们进行了一项观察性研究，回顾了所有关于青少年接种新冠肺炎疫苗并记录在VigiBase(R)中的报告，VigiBase(R)是世界卫生组织的全球个案安全报告数据库。我们包括在2021年1月1日至2021年9月14日期间登记的所有报告。计算报告优势比(RORs)及其95%可信区间(CI)，以评估报告心包炎和/或心肌炎的风险。在4942例青少年接种新冠肺炎基因疫苗的报告中，我们鉴定出242例心包炎和/或心肌炎。与第一次接种新冠肺炎基因疫苗相比，第二次接种增加了报告心包炎和/或心肌炎的风险(ROR4.95；95%可信区间3.14，7.89)。男孩报告心包炎和/或心肌炎的风险是女孩的10倍，两种疫苗之间没有差异。结论这项仅包括青少年数据的调查首次表明，与第一次接种相比，第二次接种新冠肺炎基因疫苗会增加报告的心肌炎/心包炎的风险，特别是在男孩中，而托齐那美兰和拉沙美兰之间没有显着差异。
Aims While some concerns about vaccination-related pericarditis and/or myocarditis have been raised, no published data are available on pericarditis and/or myocarditis with mRNA COVID-19 vaccines in the age group of adolescents, particularly 12-15 years. The objective of this study was to determine whether the risk of reporting pericarditis and/or myocarditis with mRNA COVID-19 vaccines varied according to dose of vaccination, age, sex, and type of pericarditis and/or myocarditis in adolescents between 12 and 17 years. Methods and results We performed an observational study reviewing all reports of adolescents vaccinated with mRNA COVID-19 vaccines and recorded in VigiBase(R), the World Health Organization global database of individual case safety reports. We included all reports registered between 1 January 2021 and 14 September 2021. Reporting odds ratios (RORs) with their 95% confidence interval (CI) were calculated to estimate the risk of reporting pericarditis and/or myocarditis. Among 4942 reports with mRNA COVID-19 vaccines in adolescents, we identified 242 pericarditis and/or myocarditis. Compared with the first dose of mRNA COVID-19 vaccines, the second dose was associated with an increased risk of reporting pericarditis and/or myocarditis (ROR 4.95; 95% CI 3.14, 7.89). The risk of reporting pericarditis and/or myocarditis was 10 times higher in boys than in girls and no difference between the two types of vaccines could be demonstrated. Conclusion This investigation including only adolescent data suggests for the first time that the second dose of mRNA COVID-19 vaccines increases the risk of reporting myocarditis/pericarditis compared with the first dose particularly in boys without significant difference between tozinameran and elasomeran.